News | July 30, 2025
Merck unveils $3 billion cost cutting plan
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
The company will provide the necessary response to USFDA within stipulated 15 days
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Delivers robust earnings performance, successfully navigating a dynamic environment
Subscribe To Our Newsletter & Stay Updated
